

Ian J Jacobs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6277509/publications.pdf>

Version: 2024-02-01

188
papers

16,769
citations

19657

61
h-index

15732

125
g-index

192
all docs

192
docs citations

192
times ranked

17160
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 110-118.	2.3	2
2	Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. Journal of Medical Genetics, 2022, 59, 632-643.	3.2	33
3	Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Cancers, 2021, 13, 858.	3.7	6
4	UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. Trials, 2021, 22, 173.	1.6	4
5	Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet, The, 2021, 397, 2182-2193.	13.7	313
6	Completeness and accuracy of national cancer and death registration for outcome ascertainment in trialsâ€”an ovarian cancer exemplar. Trials, 2021, 22, 88.	1.6	7
7	Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses. American Journal of Obstetrics and Gynecology, 2020, 222, 56.e1-56.e17.	1.3	25
8	Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. Cancers, 2020, 12, 1931.	3.7	18
9	Ovarian cancer symptoms, routes to diagnosis and survival â€” Population cohort study in the â€”no screenâ€” arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecologic Oncology, 2020, 158, 316-322.	1.4	29
10	Socioeconomic Status and Ovarian Cancer Stage at Diagnosis: A Study Nested Within UKCTOCS. Diagnostics, 2020, 10, 89.	2.6	5
11	Improved early detection of ovarian cancer using longitudinal multimarker models. British Journal of Cancer, 2020, 122, 847-856.	6.4	60
12	Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. British Journal of Cancer, 2019, 121, 483-489.	6.4	32
13	The 14q32 maternally imprinted locus is a major source of longitudinally stable circulating microRNAs as measured by small RNA sequencing. Scientific Reports, 2019, 9, 15787.	3.3	7
14	Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. Cancer Prevention Research, 2019, 12, 391-400.	1.5	17
15	Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis. Menopause, 2019, 26, 1100-1009.	2.0	20
16	A quantitative performance study of two automatic methods for the diagnosis of ovarian cancer. Biomedical Signal Processing and Control, 2018, 46, 86-93.	5.7	16
17	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. Journal of Medical Genetics, 2018, 55, 546-554.	3.2	38
18	Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population. Clinical Cancer Research, 2018, 24, 4726-4733.	7.0	39

#	ARTICLE	IF	CITATIONS
19	Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation. <i>BMJ: British Medical Journal</i> , 2018, 362, k2644.	2.3	43
20	Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>F1000Research</i> , 2018, 7, 1241.	1.6	2
21	Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. <i>British Journal of Cancer</i> , 2017, 116, 501-508.	6.4	86
22	The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT. <i>British Journal of Cancer</i> , 2017, 116, 1111-1117.	6.4	8
23	Change-point of multiple biomarkers in women with ovarian cancer. <i>Biomedical Signal Processing and Control</i> , 2017, 33, 169-177.	5.7	13
24	Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5912-5922.	7.0	47
25	Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , 2017, 7, e011822.	1.9	8
26	Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMC Public Health</i> , 2017, 17, 603.	2.9	11
27	A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. <i>British Journal of Cancer</i> , 2017, 117, 666-674.	6.4	47
28	Impact of a decision aid about stratified ovarian cancer risk-management on women's knowledge and intentions: a randomised online experimental survey study. <i>BMC Public Health</i> , 2017, 17, 882.	2.9	10
29	Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1411-1420.	1.6	148
30	Novel risk models for early detection and screening of ovarian cancer. <i>Oncotarget</i> , 2017, 8, 785-797.	1.8	13
31	Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. <i>Oncotarget</i> , 2017, 8, 3811-3825.	1.8	45
32	Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>PLoS ONE</i> , 2016, 11, e0165539.	2.5	8
33	Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: Case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS). <i>Steroids</i> , 2016, 110, 62-69.	1.8	16
34	Protein Z: A putative novel biomarker for early detection of ovarian cancer. <i>International Journal of Cancer</i> , 2016, 138, 2984-2992.	5.1	41
35	Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 945-956.	13.7	791
36	Genetic screening for gynecological cancer: where are we heading?. <i>Future Oncology</i> , 2016, 12, 207-220.	2.4	11

#	ARTICLE	IF	CITATIONS
37	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. <i>Clinical Cancer Research</i> , 2016, 22, 1734-1743.	7.0	69
38	Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	22
39	Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1519-1525.	2.5	10
40	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. <i>Genome Medicine</i> , 2015, 7, 108.	8.2	138
41	Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease Detection. <i>Clinical Cancer Research</i> , 2015, 21, 622-631.	7.0	158
42	Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, 379.	6.3	146
43	Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family History-Based Testing. <i>Journal of the National Cancer Institute</i> , 2015, 107, 380.	6.3	135
44	Socioeconomic indicators of health inequalities and female mortality: a nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMC Public Health</i> , 2015, 15, 253.	2.9	9
45	Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. <i>Journal of Clinical Oncology</i> , 2015, 33, 2062-2071.	1.6	166
46	Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy. <i>Menopause</i> , 2015, 22, 384-390.	2.0	25
47	A risk prediction algorithm for ovarian cancer incorporating <i>BRCA1</i> , <i>BRCA2</i> , common alleles and other familial effects. <i>Journal of Medical Genetics</i> , 2015, 52, 465-475.	3.2	52
48	Contribution of Germline Mutations in the <i>RAD51B</i> , <i>RAD51C</i> , and <i>RAD51D</i> Genes to Ovarian Cancer in the Population. <i>Journal of Clinical Oncology</i> , 2015, 33, 2901-2907.	1.6	266
49	Germline Mutations in the <i>BRIP1</i> , <i>BARD1</i> , <i>PALB2</i> , and <i>NBN</i> Genes in Women With Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	311
50	Multiprobabilistic prediction in early medical diagnoses. <i>Annals of Mathematics and Artificial Intelligence</i> , 2015, 74, 203-222.	1.3	9
51	Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. <i>Journal of Medical Genetics</i> , 2014, 51, 108-113.	3.2	58
52	Validity of self-reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , 2014, 4, e004421.	1.9	15
53	Association of skirt size and postmenopausal breast cancer risk in older women: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , 2014, 4, e005400-e005400.	1.9	8
54	Cancer-associated autoantibodies to MUC1 and MUC4—A blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. <i>International Journal of Cancer</i> , 2014, 134, 2180-2188.	5.1	49

#	ARTICLE	IF	CITATIONS
55	A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. <i>Genome Medicine</i> , 2014, 6, 47.	8.2	53
56	Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. <i>Proteomics - Clinical Applications</i> , 2014, 8, 982-993.	1.6	41
57	In vitro three-dimensional modeling of fallopian tube secretory epithelial cells. <i>BMC Cell Biology</i> , 2013, 14, 43.	3.0	40
58	Microarray Glycoprofiling of CA125 Improves Differential Diagnosis of Ovarian Cancer. <i>Journal of Proteome Research</i> , 2013, 12, 1408-1418.	3.7	96
59	Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 472-477.	1.7	14
60	Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development. <i>PLoS Medicine</i> , 2013, 10, e1001551.	8.4	135
61	Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule. <i>Journal of Clinical Oncology</i> , 2013, 31, 49-57.	1.6	126
62	Final results of 4-monthly screening in the UK Familial Ovarian Cancer Screening Study (UKFOCSS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	10
63	The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women's Cancer. <i>PLoS Genetics</i> , 2012, 8, e1002517.	3.5	111
64	Predictive Value of Symptoms for Ovarian Cancer: Comparison of Symptoms Reported by Questionnaire, Interview, and General Practitioner Notes. <i>Journal of the National Cancer Institute</i> , 2012, 104, 114-124.	6.3	49
65	Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. <i>Endocrine-Related Cancer</i> , 2012, 19, 137-147.	3.1	36
66	The UKCTOCS Experienceâ€”Reasons for Hope?. <i>International Journal of Gynecological Cancer</i> , 2012, 22, S18-S20.	2.5	20
67	Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). <i>Archives of Gynecology and Obstetrics</i> , 2012, 286, 1555-1562.	1.7	38
68	Conformal predictors in early diagnostics of ovarian and breast cancers. <i>Progress in Artificial Intelligence</i> , 2012, 1, 245-257.	2.4	14
69	Withdrawal from familial ovarian cancer screening for surgery: Findings from a psychological evaluation study (PsyFOCS). <i>Gynecologic Oncology</i> , 2012, 124, 158-163.	1.4	12
70	Multiprobabilistic Venn Predictors with Logistic Regression. <i>International Federation for Information Processing</i> , 2012, , 224-233.	0.4	5
71	Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. <i>Trials</i> , 2011, 12, 61.	1.6	40
72	Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 525-530.	5.0	30

#	ARTICLE	IF	CITATIONS
73	Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKTOCS cohort. <i>Lancet Oncology</i> , The, 2011, 12, 38-48.	10.7	176
74	Can Ovarian Cancer Screening Save Lives? The Question Remains Unanswered. <i>Obstetrics and Gynecology</i> , 2011, 118, 1209-1211.	2.4	13
75	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2011, 128, 2063-2074.	5.1	54
76	The <i>Sine Qua Non</i> of Discovering Novel Biomarkers for Early Detection of Ovarian Cancer: Carefully Selected Preclinical Samples. <i>Cancer Prevention Research</i> , 2011, 4, 299-302.	1.5	15
77	Modelling genetic and clinical heterogeneity in epithelial ovarian cancers. <i>Carcinogenesis</i> , 2011, 32, 1540-1549.	2.8	36
78	A wellâ€characterised peak identification list of MALDI MS profile peaks for human blood serum. <i>Proteomics</i> , 2010, 10, 3388-3392.	2.2	32
79	Polymorphism in the <i>GALNT1</i> Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women: The Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 600-604.	2.5	23
80	Peptides Generated Ex Vivo from Serum Proteins by Tumor-Specific Exopeptidases Are Not Useful Biomarkers in Ovarian Cancer. <i>Clinical Chemistry</i> , 2010, 56, 262-271.	3.2	31
81	Senescent Fibroblasts Promote Neoplastic Transformation of Partially Transformed Ovarian Epithelial Cells in a Three-dimensional Model of Early Stage Ovarian Cancer. <i>Neoplasia</i> , 2010, 12, 317-IN3.	5.3	78
82	Microcell-Mediated Chromosome Transfer Identifies EPB41L3 as a Functional Suppressor of Epithelial Ovarian Cancers. <i>Neoplasia</i> , 2010, 12, 579-IN18.	5.3	38
83	Development of a Multimarker Assay for Early Detection of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2159-2166.	1.6	246
84	Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. <i>Genome Research</i> , 2010, 20, 440-446.	5.5	740
85	Clinical Value of Immunohistochemically Detected Lymphatic and Vascular Invasions in Clinically Staged Endometrioid Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1074-1079.	2.5	21
86	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. <i>Human Molecular Genetics</i> , 2009, 18, 2297-2304.	2.9	42
87	Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. <i>Human Molecular Genetics</i> , 2009, 18, 1869-1878.	2.9	17
88	Single Nucleotide Polymorphisms in the <i>TP53</i> Region and Susceptibility to Invasive Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2009, 69, 2349-2357.	0.9	63
89	Chromosomes 6 and 18 induce neoplastic suppression in epithelial ovarian cancer cells. <i>International Journal of Cancer</i> , 2009, 124, 1037-1044.	5.1	11
90	The clonal evolution of metastases from primary serous epithelial ovarian cancers. <i>International Journal of Cancer</i> , 2009, 124, 1579-1586.	5.1	68

#	ARTICLE	IF	CITATIONS
91	HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: A proof of principle study. <i>International Journal of Cancer</i> , 2009, 125, 2214-2218.	5.1	59
92	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. <i>Nature Genetics</i> , 2009, 41, 996-1000.	21.4	276
93	Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Lancet Oncology</i> , The, 2009, 10, 327-340.	10.7	738
94	Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. <i>Current Opinion in Obstetrics and Gynecology</i> , 2009, 21, 31-38.	2.0	23
95	An Epigenetic Signature in Peripheral Blood Predicts Active Ovarian Cancer. <i>PLoS ONE</i> , 2009, 4, e8274.	2.5	291
96	<i>HOXA11</i> DNA methylation—A novel prognostic biomarker in ovarian cancer. <i>International Journal of Cancer</i> , 2008, 123, 725-729.	5.1	97
97	Clinical Value of Immunohistochemically Detected Lymphovascular Space Invasion in Early Stage Cervical Carcinoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 2581-2588.	1.5	30
98	Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas. <i>Apmis</i> , 2008, 116, 400-409.	2.0	16
99	Predicting Clinical Outcome in Patients Diagnosed with Synchronous Ovarian and Endometrial Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 5840-5848.	7.0	41
100	The Effects of Common Genetic Variants in Oncogenes on Ovarian Cancer Survival. <i>Clinical Cancer Research</i> , 2008, 14, 5833-5839.	7.0	32
101	<i>BRCA1</i> and <i>BRCA2</i> Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark. <i>Clinical Cancer Research</i> , 2008, 14, 3761-3767.	7.0	92
102	Recruitment to multicentre trials—lessons from UKCTOCS: descriptive study. <i>BMJ: British Medical Journal</i> , 2008, 337, a2079-a2079.	2.3	128
103	Epigenotyping in Peripheral Blood Cell DNA and Breast Cancer Risk: A Proof of Principle Study. <i>PLoS ONE</i> , 2008, 3, e2656.	2.5	131
104	Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish “MALOVA” ovarian cancer study. <i>Pathology</i> , 2008, 40, 487-492.	0.6	20
105	Distribution of Microsatellite Instability in Danish Ovarian Tumor Patients and the Prognostic Value in Ovarian Cancer Patients. <i>Oncology Research</i> , 2008, 17, 43-49.	1.5	4
106	Preanalytic Influence of Sample Handling on SELDI-TOF Serum Protein Profiles. <i>Clinical Chemistry</i> , 2007, 53, 645-656.	3.2	131
107	Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2007, 67, 3027-3035.	0.9	78
108	Decline in use of hormone therapy among postmenopausal women in the United Kingdom. <i>Menopause</i> , 2007, 14, 462-467.	2.0	36

#	ARTICLE	IF	CITATIONS
109	Tagging Single Nucleotide Polymorphisms in the BRIP1 Gene and Susceptibility to Breast and Ovarian Cancer. PLoS ONE, 2007, 2, e268.	2.5	54
110	Contribution of <i>BRCA1</i> and <i>BRCA2</i> mutations to inherited ovarian cancer. Human Mutation, 2007, 28, 1207-1215.	2.5	76
111	Screening for the <i>BRCA1</i> -ins6kbEx13 mutation: potential for misdiagnosis. Human Mutation, 2007, 28, 525-526.	2.5	8
112	Serum Peptide Profiling using MALDI Mass Spectrometry. Proteomics, 2007, 7, 77-89.	2.2	51
113	Epigenetic stem cell signature in cancer. Nature Genetics, 2007, 39, 157-158.	21.4	1,023
114	ESGO statement on cervical cancer vaccination: August 2007. International Journal of Gynecological Cancer, 2007, 17, 1183-1185.	2.5	7
115	CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. Gynecologic Oncology, 2007, 104, 508-515.	1.4	122
116	Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer From the Danish "MALOVA" Ovarian Cancer Study. Gynecologic Oncology, 2007, 106, 318-324.	1.4	19
117	Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecologic Oncology, 2007, 107, 526-531.	1.4	96
118	Ovarian Cancer Screening. , 2006, , 47-68.		1
119	Screening for Ovarian Cancer. Clinical Obstetrics and Gynecology, 2006, 49, 433-447.	1.1	69
120	Familial ovarian cancer screening. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2006, 20, 321-338.	2.8	16
121	Common Variants in RB1 Gene and Risk of Invasive Ovarian Cancer. Cancer Research, 2006, 66, 10220-10226.	0.9	39
122	Low frequency of <i>BRAF</i> and <i>CDKN2A</i> mutations in endometrial cancer. International Journal of Cancer, 2005, 115, 930-934.	5.1	46
123	Diagnostic Performance of Nanoparticle-Enhanced Magnetic Resonance Imaging in the Diagnosis of Lymph Node Metastases in Patients With Endometrial and Cervical Cancer. Journal of Clinical Oncology, 2005, 23, 2813-2821.	1.6	327
124	Prospective Study Using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer. Journal of Clinical Oncology, 2005, 23, 7919-7926.	1.6	218
125	Screening for Familial Ovarian Cancer: The Need for Well-Designed Prospective Studies. Journal of Clinical Oncology, 2005, 23, 5443-5445.	1.6	28
126	Preoperative Sensitivity and Specificity for Early-Stage Ovarian Cancer When Combining Cancer Antigen CA-125II, CA 15-3, CA 72-4, and Macrophage Colony-Stimulating Factor Using Mixtures of Multivariate Normal Distributions. Journal of Clinical Oncology, 2004, 22, 4059-4066.	1.6	156

#	ARTICLE	IF	CITATIONS
127	Significance of PTEN alterations in endometrial carcinoma: A population-based study of mutations, promoter methylation and PTEN protein expression. International Journal of Oncology, 2004, 25, 1615.	3.3	25
128	Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer. Cancer Research, 2004, 64, 5882-5890.	0.9	884
129	A Molecular Genetic and Statistical Approach for the Diagnosis of Dual-Site Cancers. Journal of the National Cancer Institute, 2004, 96, 1441-1446.	6.3	44
130	A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. Laboratory Investigation, 2004, 84, 923-931.	3.7	30
131	Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma. Cancer, 2004, 100, 2387-2395.	4.1	11
132	Progress and Challenges in Screening for Early Detection of Ovarian Cancer. Molecular and Cellular Proteomics, 2004, 3, 355-366.	3.8	375
133	High-Risk Premenopausal Women's Experiences of Undergoing Prophylactic Oophorectomy: A Descriptive Study. Genetic Testing and Molecular Biomarkers, 2004, 8, 148-156.	1.7	28
134	Screening and Diagnosis of Ovarian Cancer in the General Population. , 2004, , 355-368.		3
135	Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis. Gynecologic Oncology, 2003, 91, 218-225.	1.4	16
136	MSI-low, a real phenomenon which varies in frequency among cancer types. Journal of Pathology, 2003, 201, 389-394.	4.5	47
137	Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. Journal of Pathology, 2003, 201, 544-554.	4.5	127
138	Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal Women. Journal of Clinical Oncology, 2003, 21, 206s-210.	1.6	219
139	Characterization of Adnexal Mass Lesions on MR Imaging. American Journal of Roentgenology, 2003, 180, 1297-1304.	2.2	186
140	CA125 and Other Tumor Markers in Screening and Monitoring of Ovarian Cancer. , 2003, , 193-200.		2
141	MR Imaging of Carcinoma of the Vulva. American Journal of Roentgenology, 2002, 178, 373-377.	2.2	102
142	Ovarian cancer screening. British Journal of Hospital Medicine, 2002, 63, 210-213.	0.2	10
143	Management of familial ovarian cancer. , 2002, , 275-285.		1
144	Screening for familial ovarian cancer. , 2002, , 220-234.		3

#	ARTICLE	IF	CITATIONS
145	Screening for ovarian cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 469-482.	2.8	43
146	Molecular evidence of a common clonal origin and subsequent divergent clonal evolution in vulval intraepithelial neoplasia, vulval squamous cell carcinoma and lymph node metastases. International Journal of Cancer, 2002, 99, 549-554.	5.1	47
147	Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clinical Cancer Research, 2002, 8, 138-43.	7.0	39
148	Survival analysis in familial ovarian cancer, a case control study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2001, 98, 219-223.	1.1	21
149	Molecular quantification and mapping of lymph-node micrometastases in cervical cancer. Lancet, The, 2001, 357, 15-20.	13.7	169
150	Ovarian cancer screening in the general population. Current Opinion in Obstetrics and Gynecology, 2001, 13, 61-64.	2.0	36
151	Ascites and a Raised Serum Ca 125â€“Confusing Combination. Journal of the Royal Society of Medicine, 2001, 94, 581-582.	2.0	20
152	PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. International Journal of Cancer, 2001, 91, 22-26.	5.1	270
153	High frequency of loss of heterozygosity in vulval intraepithelial neoplasia (VIN) is associated with invasive vulval squamous cell carcinoma (VSCC). International Journal of Cancer, 2001, 94, 896-900.	5.1	22
154	Comparative Genomic Hybridization of Microdissected Familial Ovarian Carcinoma: Two Deleted Regions on Chromosome 15q Not Previously Identified in Sporadic Ovarian Carcinoma. Laboratory Investigation, 2001, 81, 1363-1370.	3.7	25
155	Screening Based on the Risk of Cancer Calculation From Bayesian Hierarchical Change-point and Mixture Models of Longitudinal Markers. Journal of the American Statistical Association, 2001, 96, 429-439.	3.1	125
156	Recent developments in ovarian cancer screening. Current Opinion in Obstetrics and Gynecology, 2000, 12, 39-42.	2.0	95
157	Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. International Journal of Cancer, 2000, 89, 519-523.	5.1	22
158	Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 1069-1074.	2.3	33
159	Patterns in the incidence of age-related ovarian cancer in South East England 1967-1996. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 1094-1096.	2.3	10
160	Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 165-169.	2.3	64
161	Ovarian cancer screening in the general population. Ultrasound in Obstetrics and Gynecology, 2000, 15, 350-353.	1.7	26
162	Molecular Evidence Linking Primary Cancer of the Fallopian Tube to BRCA1 Germline Mutations. Gynecologic Oncology, 2000, 76, 45-50.	1.4	186

#	ARTICLE	IF	CITATIONS
163	Registration of ovarian cancer in England and Wales. British Journal of Cancer, 2000, 83, 279-279.	6.4	1
164	Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. Cancer, 1999, 85, 2068-2072.	4.1	17
165	OVX1 Radioimmunoassay Results Are Dependent on the Method of Sample Collection and Storage. Clinical Chemistry, 1999, 45, 692-694.	3.2	16
166	Role of MR Imaging in the Selection of Patients with Early Cervical Carcinoma for Fertility-preserving Surgery: Initial Experience. Radiology, 1999, 212, 395-399.	7.3	121
167	Combination of Multiple Serum Markers Using an Artificial Neural Network to Improve Specificity in Discriminating Malignant from Benign Pelvic Masses. Gynecologic Oncology, 1999, 73, 56-61.	1.4	71
168	Increased Mortality in Postmenopausal Women with Serum CA125 Elevation. Gynecologic Oncology, 1999, 73, 242-246.	1.4	9
169	Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. , 1999, 85, 2068-2072.		12
170	Screening for ovarian cancer. Lancet, The, 1999, 354, 510.	13.7	4
171	Screening for ovarian cancer: a pilot randomised controlled trial. Lancet, The, 1999, 353, 1207-1210.	13.7	545
172	No Evidence Exists for Methylation Inactivation of the p16 Tumor Suppressor Gene in Ovarian Carcinogenesis. Gynecologic Oncology, 1998, 68, 14-17.	1.4	19
173	p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet, The, 1998, 352, 871-872.	13.7	187
174	Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ: British Medical Journal, 1996, 313, 1355-1358.	2.3	164
175	Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer, 1995, 76, 1615-1620.	4.1	18
176	Molecular approaches to prevention and detection of epithelial ovarian cancer. Journal of Cellular Biochemistry, 1995, 59, 219-222.	2.6	20
177	Combinations of Multiple Serum Markers Are Superior to Individual Assays for Discriminating Malignant from Benign Pelvic Masses. Gynecologic Oncology, 1995, 59, 111-116.	1.4	96
178	Non-surgical aspects of ovarian cancer. Lancet, The, 1994, 343, 335-340.	13.7	17
179	Cell growth regulation in epithelial ovarian cancer. Cancer, 1993, 71, 1597-1601.	4.1	72
180	The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. BJOG: an International Journal of Obstetrics and Gynaecology, 1993, 100, 927-931.	2.3	127

#	ARTICLE	IF	CITATIONS
181	Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. BJOG: an International Journal of Obstetrics and Gynaecology, 1993, 100, 1120-1124.	2.3	38
182	Prevention of ovarian cancer: a survey of the practice of prophylactic oophorectomy by fellows and members of the Royal College of Obstetricians and Gynaecologists. BJOG: an International Journal of Obstetrics and Gynaecology, 1989, 96, 510-515.	2.3	58
183	The CA 125 tumour-associated antigen: a review of the literature. Human Reproduction, 1989, 4, 1-12.	0.9	675
184	SCREENING FOR EARLY OVARIAN CANCER. Lancet, The, 1988, 332, 171-172.	13.7	4
185	Two fetal antigens (FA-1 and FA-2) and endometrial proteins (PP12 and PP14) isolated from amniotic fluid; preliminary observations in fetal and maternal tissues. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1988, 29, 73-85.	1.1	72
186	MULTIMODAL APPROACH TO SCREENING FOR OVARIAN CANCER. Lancet, The, 1988, 331, 268-271.	13.7	213
187	The value of CA 125 serum assay in the management of ovarian cancer. Commentary. BJOG: an International Journal of Obstetrics and Gynaecology, 1987, 94, 819-820.	2.3	3
188	Screening for Ovarian Cancer. , 0, , 144-150.		0